Compare FORM & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORM | BLTE |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.0B |
| IPO Year | 2002 | 2021 |
| Metric | FORM | BLTE |
|---|---|---|
| Price | $108.80 | $154.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $98.25 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.5M | 146.1K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.43 | N/A |
| Revenue Next Year | $7.31 | $492.11 |
| P/E Ratio | $408.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.00 | $60.00 |
| 52 Week High | $160.27 | $200.00 |
| Indicator | FORM | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 51.22 |
| Support Level | $90.23 | $145.11 |
| Resistance Level | $158.56 | $160.72 |
| Average True Range (ATR) | 8.35 | 6.09 |
| MACD | 0.42 | 0.05 |
| Stochastic Oscillator | 66.50 | 52.71 |
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.